Topical Betamethasone and Clobetasol in Orabase in Oral Lichen Planus

Overview

Oral Lichen Planus (OLP) is an autoimmune, chronic inflammatory mucocutaneous disease characterized by pain and burning sensation. The major types of OLP are the following: reticular, atrophic, erosive-ulcerative, bullous and pigmentous form.Its etiology remains unclear. The presence of auto-cytotoxic T cell clones in the lesions suggests the role of autoimmunity. Numerous treatment options of OLP include topical and systemic agents depending on severity of lesions . Topical corticosteroids abide the mainstay of therapy,and are widely accepted as the primary treatment of choice.Hence this study is designed to evaluate and compare the clinical efficacy of topical Clobetasol 0.05% in orabase and Betamethasone 0.05% in orabase in combination with Clotrimazole 1% in the management of symptomatic Oral Lichen Planus.

Full Title of Study: “A Comparative Study on Clinical Efficacy of Clobetasol and Betamethasone in Orabase in Combination With Clotrimazole, in Oral Lichen Planus”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: March 2018

Detailed Description

Patients of either sex, irrespective of age attending the Department of Oral Medicine & Radiology, Panineeya Mahavidhyalaya Institute of Dental Sciences and Research Centre, Hyderabad who are clinically and histopathologically diagnosed with Oral Lichen Planus shall be included in the study group after obtaining an informed consent from the patients.

Study design: Prospective study.

Sample size:

A total of 30 patients will be randomly divided into 2 groups with 15 patients in each group.

Methodology:

30 patients who are diagnosed with Oral Lichen Planus by clinical and histopathological examination will be randomly assigned into 2 drug groups and burning sensation will be assessed by VAS Scale and also clinical improvement will be assessed at interval of 1 week till 4 weeks.

GROUP A: This group of patients will receive topical Clobetasol 0.05% in orabase and Clotrimazole 1%.

GROUP B: This group of patients will receive topical Betamethasone 0.05% in orabase and Clotrimazole 1%.

Inclusion criteria:

1. Patients with Oral Lichen Planus, who are willing to participate in the study.

2. Patients who are physically healthy and well oriented in time, space and as a person.

3. Patients clinically and histopathologically diagnosed with Oral Lichen Planus.

4. Patients with symptoms i.e. pain and burning sensation due to oral lichen planus.

Exclusion Criteria :

1. Patients with Oral Lichen Planus, who are not willing to participate in the study.

2. Patients with any other mucosal disease or any other skin disease which may be associated with oral lesions.

3. Patients with a known allergy or contraindication to study medications.

4. Patients with systemic diseases, where steroids are contraindicated.

5. Pregnant women.

Interventions

  • Drug: Betamethasone Dipropionate
  • Drug: Clobetasol Propionate

Arms, Groups and Cohorts

  • Experimental: Betamethasone dipropionate 0.05%
    • topical Betamethasone dipropionate 0.05% in orabase with clotrimazole 1% in oral lichen planus two times a day for one month
  • Active Comparator: Clobetasol propionate 0.05%
    • Topical Clobetasol propionate 0.05% in orabase with clotrimazole 1% in oral lichen planus patients two times a day for a month

Clinical Trial Outcome Measures

Primary Measures

  • Based on Visual analog scale and size of the lesion
    • Time Frame: Each patient will be assessed for a total time frame of 1 month at a regular interval of 1 week.
    • study is in progress

Participating in This Clinical Trial

Inclusion Criteria

1. Patients with Oral Lichen Planus, who are willing to participate in the study.

2. Patients who are physically healthy and well oriented in time, space and as a person.

3. Patients clinically and histopathologically diagnosed with Oral Lichen Planus.

4. Patients with symptoms i.e. pain and burning sensation due to oral lichen planus.

Exclusion Criteria

1. Patients with Oral Lichen Planus, who are not willing to participate in the study.

2. Patients with any other mucosal disease or any other skin disease which may be associated with oral lesions.

3. Patients with a known allergy or contraindication to study medications.

4. Patients with known history of systemic diseases, where steroids are contraindicated.

5. Pregnant women.

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Garlapati Komali
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: Garlapati Komali, PROFESSOR – Panineeya Mahavidyalaya Institute of Dental Sciences & Research Centre
  • Overall Official(s)
    • KOMALI GARLAPATI, Principal Investigator, PMVIDS & RC
  • Overall Contact(s)
    • KOMALI GARLAPATI, Professor, +918008884945, komali_garlapati@yahoo.co.in

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.